These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 4203582)

  • 1. [Siderinuria caused by deferoxamine. II. The siderinuric increment obtained by association with ascorbic acid].
    Cartei G; Chisesi T; Cazzavillan M; Battista R; Barbui T; Dini E
    Haematologica; 1973; 58(11):671-88. PubMed ID: 4203582
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 3. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
    Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF
    Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of ascorbic acid on desferrioxamine therapy.
    Cartei G; Meani A
    Acta Vitaminol Enzymol; 1970; 24(6):209-13. PubMed ID: 5537933
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effects of ascorbic acid on desferrioxamine-induced siderinuria].
    Bosello O; Mengoli C; Rossi G
    Fracastoro; 1971; 64(5):310-9. PubMed ID: 5151104
    [No Abstract]   [Full Text] [Related]  

  • 7. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 8. [Urinary iron after desferrioxamine. I. Effectiveness and tolerance of high doses of the drug].
    Cartei G; Cazzavillan M; Chisesi T; Franchi F; Barbui T; Dini E
    Haematologica; 1972; 58(9):605-21. PubMed ID: 4206237
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical management of beta-thalassemia.
    Graziano J; Piomelli S
    Tex Rep Biol Med; 1980-1981; 40():355-64. PubMed ID: 7034276
    [No Abstract]   [Full Text] [Related]  

  • 10. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
    O'Brien RT
    Ann N Y Acad Sci; 1974; 232(0):221-5. PubMed ID: 4528431
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion haemosiderosis and chelation therapy.
    Ley TJ; Griffith P; Nienhuis AW
    Clin Haematol; 1982 Jun; 11(2):437-64. PubMed ID: 7042160
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 14. [Medivitan, an addition to our therapeutic possibilities].
    Grebe H
    Dtsch Med J; 1969 Jan; 20(2):74-7. PubMed ID: 5785577
    [No Abstract]   [Full Text] [Related]  

  • 15. [Disorders of iron metabolism in liver patients].
    Stromeyer G
    Internist (Berl); 1966 Jan; 7(1):33-42. PubMed ID: 4861683
    [No Abstract]   [Full Text] [Related]  

  • 16. Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid.
    Sharma DC; Mathur R
    Indian J Physiol Pharmacol; 1995 Oct; 39(4):403-6. PubMed ID: 8582755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.
    Dutta AK; Ray R; Chandra S; Bhattacharya DK
    J Assoc Physicians India; 1988 Jul; 36(7):463-4. PubMed ID: 3204100
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical and metabolic research on treatment with desferrioxamine B in various hemosiderotic erythrocyte diseases].
    Cimino R; Quattrin N
    Clin Ter; 1965 Jul; 34(1):3-32. PubMed ID: 5840761
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of diffuse liver diseases with balanced doses of vitamin B12, folic acid, ascorbic acid and nicotinamide].
    Perez Mota A
    Rev Esp Enferm Apar Dig; 1968; 27(6):933-44. PubMed ID: 4242995
    [No Abstract]   [Full Text] [Related]  

  • 20. A four year clinical evaluation of Vitron-C. A new hematinic containing ferrous fumarate and ascorbic acid.
    Kroser LS
    West Med Med J West; 1965 Nov; 6(11):314-5. PubMed ID: 5898512
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.